Posted by Michael Wonder on 26 Apr 2017
NICE backs NHS use of Lilly’s Taltz for plaque psoriasis
26 April 2017 - US pharma major Eli Lilly says that Taltz (ixekizumab) has been recommended by the NICE for use as a treatment option within the NHS in England, Wales and Northern Ireland for adults with severe plaque psoriasis who have responded inadequately to standard systemic therapies.
The NICE, the medicines cost-effectiveness watch dog, published its final appraisal determination on the use of ixekizumab today.
